Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine

Vaccine
Robin E HuebnerKeith P Klugman

Abstract

Children who had initially received three doses of either a nonavalent pneumococcal conjugate vaccine containing serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F or placebo at 6, 10, and 14 weeks of age were bled at 9 and 18 months for determination of antibody concentrations. The children were then randomized to receive a booster dose of either the 9-valent pneumococcal conjugate vaccine or a 23-valent polysaccharide vaccine and antibody levels determined 1 month later. At 9 months, the geometric mean concentrations (GMCs) were significantly higher for all vaccine serotypes in vaccinated children compared with controls (means varied from 0.49 microg/ml for serotype 4 to 2.37 microg/ml for serotype 14). At 18 months, antibody concentrations remained significantly higher in vaccinated children (means varied from 0.19 microg/ml for serotype 4 to 1.1 microg/ml for serotype 14). In children who had received conjugate vaccine in infancy, the conjugate vaccine at 18 months produced a significant booster response for serotypes 1, 6B, 14, 19F, and 23F (means varied from 2.74 microg/ml for serotype 19F to 15.52 microg/ml for serotype 6B) and produced a comparable response to a first dose of conjugate at this age for serotypes 4, 5, 9V, ...Continue Reading

References

Mar 18, 1992·JAMA : the Journal of the American Medical Association·Y Schlesinger, D M Granoff
Apr 1, 1996·The Pediatric Infectious Disease Journal·A LeachB M Greenwood
May 6, 1999·The Journal of Infectious Diseases·P RichmondK Cartwright
Sep 9, 1999·The Journal of Infectious Diseases·N MbelleK P Klugman
Sep 24, 1999·The Pediatric Infectious Disease Journal·H R ShinefieldJ Hansen
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W P HausdorffG R Siber

❮ Previous
Next ❯

Citations

Apr 21, 2012·Current Opinion in Infectious Diseases·Ray BorrowClaire-Anne Siegrist
Aug 24, 2007·The Lancet Infectious Diseases·Katherine L O'BrienDavid Goldblatt
Oct 8, 2005·Clinical and Diagnostic Laboratory Immunology·Kathryn T BiegingSandra Romero-Steiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.